**No licensed hantavirus vaccine exists as of late September 2026, and all candidates remain in early preclinical or initial Phase 1 stages.** Multiple mRNA and DNA platforms, including UTMB’s single-dose Andes virus constructs that achieved full protection in hamster models and the Moderna–Korea University collaboration, have shown immunogenicity in animals, yet none have advanced to pivotal human efficacy trials. Recent outbreaks, such as the Andes virus cluster on the MV Hondius, have spurred funding and national projects like Korea’s two-year sa-mRNA initiative, but these efforts target prototype optimization and GMP manufacturing rather than near-term licensure. Vaccine development for a low-incidence, multi-strain pathogen requires extensive safety, immunogenicity, and field-efficacy data that standard timelines place years away, even with accelerated platforms. A realistic shift would require an unforeseen regulatory fast-track or emergency authorization following another major outbreak, though current surveillance and trial registries indicate no such pathway is active before year-end.